Literature DB >> 16699530

Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation.

D H Kim1, S K Sohn, D I Won, N Y Lee, J S Suh, K B Lee.   

Abstract

The current study evaluates the role of quantitative measurement of peripheral lymphocyte subsets, especially CD4+ helper T-cell recovery, in predicting transplant outcomes including overall survival (OS) and non-relapse mortality (NRM) after allogeneic stem cell transplantation. A total of 69 allogeneic recipients were included with following diagnoses: acute myeloid leukemia 42, acute lymphoblastic leukemia 5, chronic myeloid leukemia 15, non-Hodgkin's lymphoma 5 and high-risk myelodysplastic syndrome 2. The peripheral lymphocyte subset counts (CD3+ T cells, CD3+4+ helper T cells, CD3+8+ cytotoxic T cells, CD19+ B cells, and CD56+ natural killer cells) were measured at 3, 6 and 12 months. The CD4+ helper T-cell reconstitution at 3 months was strongly correlated with OS (P<0.0001), NRM (P=0.0007), and opportunistic infections (P=0.0108) at the cutoff value of 200 x 10(6)/l CD4(+) helper T cells. Rapid CD4+ helper T-cell recovery was also associated with a higher CD4+ helper T-cell transplant dose (P=0.006) and donor type (P<0.001). An early CD4+ helper T-cell recovery at 3 months correlated with a subsequent faster helper T-cell recovery until 12 months, yet not with B-cell recovery. In a multivariate analysis, rapid recovery of CD4+ helper T cells at 3 months was a favorable prognostic factor together with higher CD34+ cell transplant dose in terms of OS (P=0.001) and NRM (P=0.005).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699530     DOI: 10.1038/sj.bmt.1705381

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  43 in total

1.  The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.

Authors:  Antonio Curti; Roberto M Lemoli; Giulia Tolomelli; Katia Mancuso; Paola Tacchetti; Francesca Patriarca; Monica Galli; Lucia Pantani; Beatrice Zannetti; Maria Rosa Motta; Simonetta Rizzi; Elisa Dan; Barbara Sinigaglia; Valeria Giudice; Andrea Olmo; Mario Arpinati; Gabriella Chirumbolo; Renato Fanin; Russell E Lewis; Laura Paris; Francesca Bonifazi; Michele Cavo
Journal:  Bone Marrow Transplant       Date:  2019-11-25       Impact factor: 5.483

Review 2.  Strategies for reconstituting and boosting T cell-based immunity following haematopoietic stem cell transplantation: pre-clinical and clinical approaches.

Authors:  Ann P Chidgey; Natalie Seach; Jarrod Dudakov; Maree V Hammett; Richard L Boyd
Journal:  Semin Immunopathol       Date:  2008-11-04       Impact factor: 9.623

3.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

Review 4.  Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications.

Authors:  Sophie Servais; Muriel Hannon; Régis Peffault de Latour; Gérard Socie; Yves Beguin
Journal:  Stem Cell Investig       Date:  2017-05-25

Review 5.  Sex steroid ablation: an immunoregenerative strategy for immunocompromised patients.

Authors:  E Velardi; J A Dudakov; M R M van den Brink
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 6.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

7.  Haploidentical hematopoietic stem cell transplantation without in vitro T-cell-depletion for the treatment of hematologic diseases.

Authors:  Xiao-Jun Huang
Journal:  Chimerism       Date:  2013-01-01

8.  Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation.

Authors:  Ryan M Kelly; Emily M Goren; Patricia A Taylor; Scott N Mueller; Heather E Stefanski; Mark J Osborn; Hamish S Scott; Elena A Komarova; Andrei V Gudkov; Georg A Holländer; Bruce R Blazar
Journal:  Blood       Date:  2009-12-04       Impact factor: 22.113

Review 9.  Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Authors:  Knut Liseth; Elisabeth Ersvaer; Tor Hervig; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2010-06-02

10.  White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.

Authors:  Haesook T Kim; David Frederick; Philippe Armand; Emily Andler; Grace Kao; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Vincent T Ho
Journal:  Am J Hematol       Date:  2014-03-03       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.